title: The booster injection of antigen during active sensitization of guinea-pig modifies the anti-anaphylactic activity of the PAF antagonist WEB 2086.
abstract: 1. Serum IgG levels of sensitized guinea-pigs bled at various times after the booster injection were evaluated and its capacity to sensitize passively lung strips from normal guinea-pigs assessed. Following the booster injection, both serum IgG and the ability to sensitize passively lung strips increased during the first week and decreased slowly thereafter. 2. The PAF antagonist WEB 2086 (3 mg kg-1, i.v.) blocked the anaphylactic bronchoconstriction induced by intravenous administration of ovalbumin (1 mg kg-1) when guinea-pigs were challenged 2 and 4 days after the booster injection, but became ineffective when tested in guinea-pigs challenged 7, 28 and 56 days after the booster injection. 3. The ability of WEB 2086 to reduce anaphylactic bronchoconstriction of guinea-pigs challenged 2 and 4 days after the booster injection was unrelated to either the selective involvement of one type of immunoglobulin, low IgG titres in sera or a reduced sensitizing capacity. 4. The booster injection, which accounts for the loss of efficacy of WEB 2086 from the fourth day thereafter, probably operates as a PAF-independent inflammatory challenge. 5. The protocol for immunisation and the day of experiment after the booster injection determines the sensitivity of the anaphylactic bronchoconstriction to inhibition of PAF antagonists.
authors.affiliation: Unité Associée Institut Pasteur/Institut National de la Santé et de la Recherche Médicale No 285, Paris, France.
authors.forename: S
authors.initials: S
authors.lastname: Desquand
authors.forename: J
authors.initials: J
authors.lastname: Lefort
authors.forename: C
authors.initials: C
authors.lastname: Dumarey
authors.forename: B B
authors.initials: BB
authors.lastname: Vargaftig
mesh_terms: D000707:Anaphylaxis / Q000276:immunology / Q000503:physiopathology / Q000517:prevention & control*; D000818:Animals; D001381:Azepines / Q000494:pharmacology*; D001772:Blood Cell Count; D001980:Bronchi / Q000276:immunology / Q000503:physiopathology; D004797:Enzyme-Linked Immunosorbent Assay; D006168:Guinea Pigs; D006632:Histamine / Q000097:blood; D007117:Immunization, Secondary; D007074:Immunoglobulin G / Q000276:immunology; D008168:Lung / Q000276:immunology; D010047:Ovalbumin / Q000276:immunology; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors*; D011863:Radioimmunoassay; D013050:Spectrometry, Fluorescence; D013929:Thromboxane B2 / Q000276:immunology; D014230:Triazoles / Q000494:pharmacology*
chemical_list: D001381:Azepines; D007074:Immunoglobulin G; D010972:Platelet Activating Factor; D014230:Triazoles; C052518:WEB 2086; D013929:Thromboxane B2; D006632:Histamine; D010047:Ovalbumin